ST. LOUIS & CAMBRIDGE, England--(BUSINESS WIRE)--Sept. 12, 2006--Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, and CeNeS Pharmaceuticals plc (AIM:CEN), a central nervous system (CNS)-focused biopharmaceutical company, announced today that they have extended their research agreement to develop catechol-O-methyltransferase (COMT) inhibitors to treat Parkinson’s disease. Terms of the agreement were not disclosed.
